Fig. 5From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi ArabiaBootstrap distribution of cost-effectiveness for the Risankizumab versus Adalimumab assuming double dosing and lowest price for Adalimumab assumptionBack to article page